Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Cash (2020 - 2025)

Historic Change in Cash for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $19.1 million.

  • Tango Therapeutics' Change in Cash rose 110518.33% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 18315.98%. This contributed to the annual value of $2.3 million for FY2024, which is 6087.18% down from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Change in Cash is $19.1 million, which was up 110518.33% from -$19.2 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Change in Cash ranged from a high of $154.1 million in Q3 2021 and a low of -$62.2 million during Q4 2021
  • For the 5-year period, Tango Therapeutics' Change in Cash averaged around $1.6 million, with its median value being -$4.3 million (2022).
  • Within the past 5 years, the most significant YoY rise in Tango Therapeutics' Change in Cash was 982586.78% (2021), while the steepest drop was 5967268.04% (2021).
  • Quarter analysis of 5 years shows Tango Therapeutics' Change in Cash stood at -$62.2 million in 2021, then surged by 35.17% to -$40.3 million in 2022, then skyrocketed by 119.46% to $7.9 million in 2023, then skyrocketed by 108.63% to $16.4 million in 2024, then rose by 16.38% to $19.1 million in 2025.
  • Its Change in Cash was $19.1 million in Q3 2025, compared to -$19.2 million in Q2 2025 and -$11.1 million in Q1 2025.